Telemonitoring for patients with multiple myeloma
The Impact of Telemonitoring on Correct Drug Use, Complications and Quality of Life Among Patients With Multiple Myeloma (MM)
This study is testing if using telemonitoring with an e-coach can help people with multiple myeloma stick to their medication better than standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Isala Academic / other |
| Locations | 1 site (Zwolle, Overijssel) |
| Trial ID | NCT05964270 on ClinicalTrials.gov |
What this trial studies
This clinical trial compares the effectiveness of telemonitoring using an e-coach for multiple myeloma patients against standard care. It aims to recruit 150 patients who have recently been diagnosed and are starting their first or second line of treatment. The primary outcome is adherence to medication, measured by pill count at 1-3 months, while secondary outcomes include various patient-reported measures such as quality of life and overall survival. Patients will provide data at multiple time points over a year to assess the impact of telemonitoring on their treatment experience.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who have recently been diagnosed with multiple myeloma and are starting their first or second line of treatment.
Not a fit: Patients with severe psychiatric illnesses or those who are too ill to engage with the intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance medication adherence and improve overall patient outcomes for those with multiple myeloma.
How similar studies have performed: Other studies have shown promise in using telemonitoring for chronic conditions, suggesting potential success for this approach in multiple myeloma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: In order to be eligible to participate in this study, a participant (patient) must meet all of the -following criteria: * signed informed consent * \>18 years * recently diagnosed MM patients with first-line or second-line treatment * able to complete patient-reported outcome measures and experiences * have minimal digital skills to check if they are able to interact with an e-coach * can read and understand Dutch. Participants who meet any of the following criteria will be excluded from participation in this study * psychiatric illness requiring secondary-care intervention * too ill to engage with the intervention in the opinion of the clinical care team * no perspective of \>12 months survival.
Where this trial is running
Zwolle, Overijssel
- Isala Klinieken — Zwolle, Overijssel, Netherlands (Recruiting)
Study contacts
- Principal investigator: Job Eijsink, PharmD — Isala klinieken department clinical pharmacy
- Study coordinator: Job Eijsink, PharmD
- Email: j.f.h.eijsink@isala.nl
- Phone: 0618885254
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.